In 2027 VGX will trade between $0.02708 and $0.03267, reflecting modest long-term growth potential. The token has seen ...

Data from Phase 2 Trial VGX-001-012 of Mizagliflozin in Post Bariatric Hypoglycemia will be Presented RALEIGH, NC / ACCESS Newswire / April 15, 2025 /Vogenx, Inc., a clinical-stage developer of novel ...